| 作成者 |
|
|
|
|
|
|
|
| 本文言語 |
|
| 出版者 |
|
|
|
| 発行日 |
|
| 収録物名 |
|
| 巻 |
|
| 開始ページ |
|
| 終了ページ |
|
| 出版タイプ |
|
| アクセス権 |
|
| Crossref DOI |
|
| 概要 |
Often, more than twenty generic (GE) drugs are developed for one brand name (B-N) drug. Each GE drug has passed the trial of bio-equivalence to the B-N drug, and its characteristics (which are general...ly expressed by AUC, Cmax, and Tmax, or one of its subsets) are close to the values for the B-N drug in each trial. However, trial-to-trial variation in the AUC, Cmax, and Tmax values is substantial. A model is developed in this paper to extract the distance between the characteristics of the GE and B-N drugs by adjusting for trial-to-trial variation. A method is proposed in this paper to use this distance for selecting better GE drugs from the list of candidates.続きを見る
|
Mendeley出力
BIC46-2014-6--Hayakawa-Yanagawa